Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Amicus Therapeutics, Inc. is a biopharmaceutical company that develops orally-administered, small molecule drugs to treat human genetic diseases. The drugs, called pharmacological chaperones, are being developed to treat Fabray, Gaucher, and Pompe disease.
Website: amicusrx.com


  • Pretty weak financial results growth rate 6.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (42.1%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.6% (LTM)
  • Share price is 4.2% higher than minimum and 57.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (55.0x vs 30.0x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: FOLD
Share price, USD:  (-0.6%)6.125
year average price 9.50  


year start price 10.05 2024-06-10

max close price 12.09 2024-08-21

min close price 5.88 2025-05-14

current price 6.16 2025-06-09
Common stocks: 307 689 207

Dividend Yield:  0.0%
FCF Yield LTM: 0.6%
EV / LTM EBITDA: 55.0x
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 4.9%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 1 895
Net Debt ($m): 193
EV (Enterprise Value): 2 088
EBITDA LTM (млн $): 38
EV / LTM EBITDA: 55.0x
Price to Book: 10.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-05-30globenewswire.com

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

2025-05-01zacks.com

Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates

2025-04-30globenewswire.com

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

2025-02-20zacks.com

FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth

2025-02-20zacks.com

Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics

2025-02-19businesswire.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

2025-02-19seekingalpha.com

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

2025-02-19zacks.com

Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates

2025-02-17globenewswire.com

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

2025-01-23globenewswire.com

NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-06 2024-08-08 2024-05-09 2024-02-28 2023-11-08 2023-08-08 2023-05-10 2023-03-01 2022-11-07
acceptedDate 2024-11-06 16:02:53 2024-08-08 16:02:15 2024-05-09 16:03:24 2024-02-28 16:08:16 2023-11-08 16:02:08 2023-08-08 16:02:13 2023-05-10 16:04:21 2023-03-01 16:07:25 2022-11-07 06:04:21
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 142M 127M 110M 115M 104M 95M 86M 88M 82M
costOfRevenue 13M 13M 16M 14M 10M 9M 7M 9M 13M
grossProfit 128M 113M 95M 102M 94M 85M 79M 79M 68M
grossProfitRatio 0.906 0.894 0.858 0.883 0.904 0.904 0.92 0.893 0.836
researchAndDevelopmentExpenses 26M 25M 28M 35M 41M 35M 41M 64M 53M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 75M 74M 88M 70M 66M 65M 74M 54M 47M
otherExpenses 0 -4M -5M -3M 4M -11M 1M 1M 1M
operatingExpenses 101M 98M 116M 105M 106M 103M 117M 119M 102M
costAndExpenses 120M 112M 132M 119M 116M 112M 124M 129M 115M
interestIncome 1M 1M 2M 2M 1M 2M 2M 2M 563 000
interestExpense 13M 13M 12M 13M -13M 12M 12M 11M 10M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M -2M -15M 15M
ebitda 22M 15M -20M -2M -29M -24M -40M -56M -18M
ebitdaratio 0.153 0.135 -0.177 -0.013 -0.282 -0.258 -0.462 -0.637 -0.218
operatingIncome 22M 15M -22M -4M -17M -19M -37M -41M -33M
operatingIncomeRatio 0.153 0.118 -0.196 -0.032 -0.164 -0.2 -0.433 -0.462 -0.407
totalOtherIncomeExpensesNet -15M -15M -22M -28M -8M -12M -16M -29M 4M
incomeBeforeTax 7M 108 000 -44M -32M -25M -41M -53M -70M -29M
incomeBeforeTaxRatio 0.048 0.001 -0.395 -0.275 -0.239 -0.429 -0.617 -0.795 -0.358
incomeTaxExpense 14M 16M 5M 2M 3M 3M -287 000 -14M 4M
netIncome -7M -16M -48M -34M -22M -43M -53M -56M -33M
netIncomeRatio -0.048 -0.124 -0.439 -0.294 -0.208 -0.457 -0.614 -0.634 -0.407
eps -0.022 -0.052 -0.16 -0.12 -0.073 -0.15 -0.18 -0.19 -0.12
epsdiluted -0.022 -0.052 -0.16 -0.12 -0.073 -0.15 -0.18 -0.19 -0.12
weightedAverageShsOut 305M 304M 303M 294M 296M 293M 291M 289M 289M
weightedAverageShsOutDil 305M 304M 303M 294M 296M 293M 291M 289M 289M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-06 2024-08-08 2024-05-09 2024-02-28 2023-11-08 2023-08-08 2023-05-10 2023-03-01 2022-11-07
acceptedDate 2024-11-06 16:02:53 2024-08-08 16:02:15 2024-05-09 16:03:24 2024-02-28 16:08:16 2023-11-08 16:02:08 2023-08-08 16:02:13 2023-05-10 16:04:21 2023-03-01 16:07:25 2022-11-07 06:04:21
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 234M 209M 210M 247M 263M 211M 161M 149M 278M
shortTermInvestments 16M 51M 30M 39M 17M 54M 107M 145M 77M
cashAndShortTermInvestments 250M 260M 240M 286M 280M 266M 267M 294M 355M
netReceivables 98M 85M 76M 88M 73M 64M 68M 66M 52M
inventory 115M 81M 61M 60M 57M 51M 27M 24M 13M
otherCurrentAssets 35M 35M 54M 50M 53M 52M 37M 40M 38M
totalCurrentAssets 498M 462M 431M 483M 463M 433M 400M 424M 459M
propertyPlantEquipmentNet 54M 54M 55M 58M 61M 58M 60M 60M 62M
goodwill 198M 198M 198M 198M 198M 198M 198M 198M 198M
intangibleAssets 18M 19M 20M 20M 21M 22M 23M 23M 23M
goodwillAndIntangibleAssets 216M 217M 217M 218M 219M 220M 221M 221M 221M
longTermInvestments 0 3M 3M 3M 3M 3M 0 0 0
taxAssets 0 0 0 0 -3M -3M 0 0 0
otherNonCurrentAssets 19M 14M 15M 15M 21M 19M 20M 19M 18M
totalNonCurrentAssets 288M 288M 291M 295M 301M 297M 301M 300M 301M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 787M 749M 722M 778M 764M 730M 701M 724M 760M
accountPayables 13M 32M 9M 15M 23M 14M 25M 15M 12M
shortTermDebt 17M 16M 8M 8M 8M 8M 8M 9M 8M
taxPayables 0 0 0 12M 0 0 0 6M 0
deferredRevenue 0 0 0 12M 0 0 0 5M 5M
otherCurrentLiabilities 128M 120M 125M 132M 139M 138M 105M 110M 140M
totalCurrentLiabilities 158M 168M 142M 168M 169M 159M 138M 139M 165M
longTermDebt 436M 436M 388M 388M 447M 444M 444M 444M 443M
deferredRevenueNonCurrent 0 0 0 0 6M 6M 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -6M -6M 0 5M 5M
otherNonCurrentLiabilities 13M 13M 61M 62M 15M 15M 16M 14M 438M
totalNonCurrentLiabilities 450M 449M 449M 450M 461M 459M 460M 462M 462M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 55M 55M 48M 49M 60M 59M 59M 60M 60M
totalLiabilities 608M 617M 591M 618M 631M 619M 598M 601M 627M
preferredStock 0 0 0 0 7M 0 0 0 0
commonStock 3M 3M 3M 3M 3M 3M 3M 3M 3M
retainedEarnings -2 755M -2 748M -2 732M -2 684M -2 650M -2 629M -2 585M -2 532M -2 477M
accumulatedOtherComprehensiveIncomeLoss 25M 9M 7M 5M -7M 4M -7M -12M -39M
othertotalStockholdersEquity 2 906M 2 869M 2 854M 2 836M 2 781M 2 733M 2 692M 2 665M 2 645M
totalStockholdersEquity 179M 133M 131M 160M 133M 112M 103M 123M 133M
totalEquity 179M 133M 131M 160M 133M 112M 103M 123M 133M
totalLiabilitiesAndStockholdersEquity 787M 749M 722M 778M 764M 730M 701M 724M 760M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 787M 749M 722M 778M 764M 730M 701M 724M 760M
totalInvestments 16M 54M 33M 42M 17M 54M 107M 145M 77M
totalDebt 445M 444M 444M 445M 454M 452M 452M 452M 451M
netDebt 211M 235M 235M 198M 191M 241M 291M 303M 173M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD FOLD
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-06 2024-08-08 2024-05-09 2024-02-28 2023-11-08 2023-08-08 2023-05-10 2023-03-01 2022-11-07
acceptedDate 2024-11-06 16:02:53 2024-08-08 16:02:15 2024-05-09 16:03:24 2024-02-28 16:08:16 2023-11-08 16:02:08 2023-08-08 16:02:13 2023-05-10 16:04:21 2023-03-01 16:07:25 2022-11-07 06:04:21
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -7M -16M -48M -34M -22M -43M -53M -56M -33M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M 1M 1M 1M
deferredIncomeTax 0 0 5M -28M 3M 20M -5M 9000 0
stockBasedCompensation 19M 16M 31M 18M 17M 17M 35M 19M 15M
changeInWorkingCapital 11M 11M -22M 696 000 -33M -5M -3M -51M -3M
accountsReceivables 0 -10M 10M -11M -11M 4M -1M -10M -3M
inventory 0 -25M -2M -2M -15M -24M -3M -10M 1M
accountsPayables -3M 27M -24M 8M 9M 32M -72 000 -32M 3M
otherWorkingCapital 14M 19M -6M 6M -16M -16M 1M 695 000 -4M
otherNonCashItems -48M 38M 60M 45M -6M -7M 7M 6M 9M
netCashProvidedByOperatingActivities -23M 23M -30M 3M -38M -16M -18M -81M -12M
investmentsInPropertyPlantAndEquipment 3M -1M -2M -2M -2M -2M -2M -3M 0
acquisitionsNet 0 0 0 22M 2M 2M 0 0 0
purchasesOfInvestments -5M -44M -30M -39M -17M -20M -17M -143M -1M
salesMaturitiesOfInvestments 40M 23M 39M 16M 54M 72M 55M 76M 76M
otherInvestingActivites -3M -1M 9M -22M -2M -2M 0 3M 137 000
netCashUsedForInvestingActivites 34M -22M 8M -24M 36M 50M 36M -67M 75M
debtRepayment 24 000 -36 000 -42 000 -21M -31 000 -23 000 -28 000 -191 000 -51 000
commonStockIssued 19M 863 000 3M 32M 37M 24M 2M 0 0
commonStockRepurchased 0 0 -17M -2M -2M -1M -13M -2M 0
dividendsPaid 0 0 0 0 0 -1M 0 0 0
otherFinancingActivites -987 000 -821 000 -17M -3M 6M 2M 3M 3M -508 000
netCashUsedProvidedByFinancingActivities 18M -857 000 -13M 8M 38M 24M -8M 557 000 -559 000
effectOfForexChangesOnCash -5M -294 000 -2M -4M 17M -8M 2M 19M -21M
netChangeInCash 24M -426 000 -37M -16M 52M 49M 12M -128M 42M
cashAtEndOfPeriod 237M 209M 210M 247M 266M 214M 165M 153M 282M
cashAtBeginningOfPeriod 212M 210M 247M 263M 214M 165M 153M 282M 240M
operatingCashFlow -23M 23M -30M 3M -38M -16M -18M -81M -12M
capitalExpenditure -356 000 -1M -2M -2M -2M -2M -2M -3M 0
freeCashFlow -23M 22M -32M 2M -40M -18M -20M -83M -12M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-05 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-06 12:00 ET
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
2024-11-01 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
2024-10-28 11:00 ET
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
2024-10-17 11:00 ET
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
2024-10-04 11:00 ET
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
2024-09-03 11:00 ET
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
2024-08-30 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
2024-08-08 11:00 ET
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
2024-07-30 11:00 ET
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
2024-06-05 11:00 ET
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-06-04 11:00 ET
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
2024-05-09 11:00 ET
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
2024-05-08 11:00 ET
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
2024-05-01 11:00 ET
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
2024-03-20 11:00 ET
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
2024-03-01 12:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
2024-02-28 12:00 ET
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
2024-02-15 12:00 ET
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
2024-02-08 12:00 ET
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
2024-02-01 12:00 ET
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
2024-01-07 21:00 ET
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
2024-01-03 12:00 ET
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 11:00 ET
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
2023-11-08 12:00 ET
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
2023-11-01 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
2023-10-27 11:00 ET
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
2023-10-03 11:00 ET
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
2023-10-02 12:20 ET
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
2023-10-02 00:30 ET
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
2023-09-28 14:41 ET
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
2023-09-01 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
2023-08-29 11:00 ET
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
2023-08-21 11:00 ET
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
2023-08-15 11:00 ET
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
2023-08-08 11:00 ET
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
2023-07-31 11:00 ET
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
2023-06-27 11:00 ET
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
2023-05-10 11:00 ET
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
2023-05-02 11:00 ET
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
2023-05-01 11:00 ET
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
2023-04-26 17:00 ET
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2023-03-28 11:05 ET
WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
2023-03-27 11:00 ET
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
2023-03-01 12:00 ET
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
2023-02-27 12:00 ET
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
2023-02-22 22:00 ET
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
2023-02-14 12:00 ET
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
2023-02-13 12:00 ET
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
2023-02-08 12:00 ET
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
2023-01-09 12:00 ET
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
2023-01-03 12:00 ET
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-16 13:10 ET
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
2022-11-15 12:00 ET
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
2022-11-07 17:20 ET
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
2022-11-07 12:00 ET
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
2022-10-28 20:01 ET
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
2022-10-27 11:00 ET
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
2022-10-11 11:00 ET
Amicus Therapeutics Announces Participation at World Muscle Society 2022
2022-09-21 11:00 ET
Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
2022-09-08 11:00 ET
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-04 11:00 ET
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
2022-07-26 11:00 ET
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
2022-06-08 11:00 ET
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-05-10 20:01 ET
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
2022-05-09 13:15 ET
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
2022-05-09 11:00 ET
Amicus Therapeutics Announces First Quarter 2022 Financial Results
2022-05-04 11:00 ET
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
2022-04-26 11:00 ET
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
2022-04-19 11:00 ET
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
2022-03-16 11:00 ET
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
2022-03-10 12:00 ET
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
2022-03-01 12:00 ET
Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
2022-02-24 12:00 ET
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
2022-02-24 12:00 ET
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions
2022-02-10 12:00 ET
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022
2022-02-07 12:00 ET
Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022
2022-01-10 12:00 ET
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
2022-01-05 12:00 ET
Amicus Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-03 12:00 ET
European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease
2021-11-24 12:00 ET
Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference
2021-11-22 12:00 ET
Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
2021-11-18 12:00 ET
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
2021-11-11 12:00 ET
Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
2021-11-09 12:00 ET
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
2021-11-03 11:00 ET
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
2021-09-29 10:30 ET
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
2021-09-29 10:30 ET
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
2021-09-20 11:00 ET
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
2021-09-03 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
2021-08-05 11:00 ET
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
2021-08-04 11:00 ET
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
2021-08-02 11:00 ET
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
2021-07-27 11:00 ET
Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
2021-06-14 11:00 ET
Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors
2021-06-08 11:00 ET
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
2021-05-28 11:00 ET
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-21 11:00 ET
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
2021-05-10 11:00 ET
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
2021-05-07 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
2021-05-06 11:00 ET
Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
2021-05-05 11:00 ET
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
2021-05-03 11:00 ET
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
2021-04-28 11:00 ET
Amicus Therapeutics Recognized as a Great Place to Work® in Europe
2021-04-26 11:00 ET
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
2021-03-15 11:00 ET
Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference
2021-03-01 12:00 ET
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
2021-02-18 12:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences
2021-02-17 12:00 ET
Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
2021-02-11 21:01 ET
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
2021-02-08 19:30 ET
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
2021-02-08 19:30 ET
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
2021-01-21 12:00 ET
Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021
2021-01-11 12:00 ET
Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook
2021-01-05 12:00 ET
Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-07 12:00 ET
Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020
2020-12-02 12:00 ET
Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors
2020-12-01 12:00 ET
Amicus Therapeutics Initiates Rolling Biologic License Application to the U.S. Food and Drug Administration for AT-GAA in Late-Onset Pompe Disease
2020-11-23 12:00 ET
Amicus Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
2020-11-05 12:00 ET
Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
2020-11-02 12:00 ET
Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
2020-10-22 11:00 ET
Amicus Therapeutics to Announce Third Quarter 2020 Financial Results on November 5, 2020
2020-10-12 11:00 ET
Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society
2020-09-24 11:00 ET
Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy
2020-09-03 11:00 ET
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2020
2020-08-10 11:00 ET
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
2020-08-04 11:00 ET
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
2020-07-28 11:00 ET
Amicus Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
2020-07-17 11:31 ET
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
2020-06-04 11:00 ET
Amicus Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
2020-05-08 11:00 ET
Amicus Therapeutics Announces Virtual 2020 Annual Meeting of Shareholders
2020-05-07 11:00 ET
Amicus Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
2020-05-05 11:00 ET
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
2020-04-24 11:00 ET
Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020
2020-03-23 11:00 ET
Amicus Therapeutics Confirms Business Continuity, 2020 Strategic Priorities and Announces Proactive Efforts to Support Public Health Initiatives, Patients & Employees
2020-03-05 12:00 ET
Amicus Opens New Global Research and Gene Therapy Center of Excellence in Philadelphia
2020-03-02 12:00 ET
Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates
2020-02-26 12:00 ET
Amicus Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference
2020-02-19 12:00 ET
Amicus Therapeutics to Announce Full-Year 2019 Financial Results on March 2, 2020
2020-02-07 12:00 ET
Amicus Therapeutics Announces Presentations and Posters at 16th Annual WORLDSymposium™ 2020
2020-01-13 12:00 ET
Amicus Therapeutics Provides Full-Year 2020 Strategic Outlook and Financial Guidance
2020-01-09 12:00 ET
Amicus Therapeutics Announces Preliminary 2019 Galafold Revenue - Exceeding Upper End of Prior Guidance
2020-01-07 12:00 ET
Amicus Therapeutics Provides Updates on Clinical, Regulatory and Manufacturing Advancements for AT-GAA for Pompe Disease
2019-11-11 12:00 ET
Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
2019-10-30 11:00 ET
Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019
2019-10-24 11:00 ET
Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
2019-10-10 11:30 ET
Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day
2019-10-02 11:00 ET
Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society
2019-10-01 11:00 ET
Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019

SEC forms

Show financial reports only

SEC form 10
2025-05-01 20:02 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 11:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 11:00 ET
Amicus Therapeutics reported for 2025 q1
SEC form 8
2025-05-01 11:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 10:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 10:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 10:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Amicus Therapeutics published news for 2025 q1
SEC form 10
2025-02-19 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Amicus Therapeutics reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Amicus Therapeutics published news for 2024 q4
SEC form 10
2024-11-06 16:02 ET
Amicus Therapeutics reported for 2024 q3
SEC form 8
2024-11-06 07:01 ET
Amicus Therapeutics published news for 2024 q3
SEC form 8
2024-11-06 07:01 ET
Amicus Therapeutics reported for 2024 q3
SEC form 8
2024-11-06 07:01 ET
Amicus Therapeutics published news for 2024 q3
SEC form 10
2024-08-08 16:02 ET
Amicus Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 07:01 ET
Amicus Therapeutics published news for 2024 q2
SEC form 8
2024-08-08 07:01 ET
Amicus Therapeutics reported for 2024 q2
SEC form 8
2024-08-08 07:01 ET
Amicus Therapeutics published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Amicus Therapeutics published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Amicus Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Amicus Therapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Amicus Therapeutics reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Amicus Therapeutics published news for 2024 q1
SEC form 10
2024-02-28 16:08 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-02-28 07:02 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-02-28 07:02 ET
Amicus Therapeutics reported for 2023 q4
SEC form 8
2024-02-28 07:02 ET
Amicus Therapeutics published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Amicus Therapeutics published news for 2023 q4
SEC form 10
2023-11-08 16:02 ET
Amicus Therapeutics published news for 2023 q3
SEC form 8
2023-11-08 07:00 ET
Amicus Therapeutics reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Amicus Therapeutics published news for 2023 q3
SEC form 10
2023-08-08 16:02 ET
Amicus Therapeutics published news for 2023 q2
SEC form 6
2023-08-08 07:00 ET
Amicus Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Amicus Therapeutics published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Amicus Therapeutics published news for 2023 q2
SEC form 6
2023-07-13 17:00 ET
Amicus Therapeutics published news for 2023 q2
SEC form 6
2023-06-27 07:01 ET
Amicus Therapeutics published news for 2023 q1
SEC form 6
2023-06-13 16:30 ET
Amicus Therapeutics published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Amicus Therapeutics published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Amicus Therapeutics reported for 2023 q1
SEC form 6
2023-03-27 07:00 ET
Amicus Therapeutics published news for 2022 q4
SEC form 10
2023-03-01 16:07 ET
Amicus Therapeutics reported for 2022 q4
SEC form 6
2023-03-01 07:01 ET
Amicus Therapeutics published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Amicus Therapeutics reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Amicus Therapeutics reported for 2022 q4
SEC form 6
2023-02-22 17:27 ET
Amicus Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 07:01 ET
Amicus Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Amicus Therapeutics published news for 2022 q4
SEC form 6
2022-12-28 17:00 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-12-16 08:17 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-16 07:01 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 14:31 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 07:22 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-11-07 07:01 ET
Amicus Therapeutics published news for 2022 q3
SEC form 10
2022-11-07 06:04 ET
Amicus Therapeutics reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Amicus Therapeutics reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Amicus Therapeutics reported for 2022 q3
SEC form 6
2022-10-28 17:18 ET
Amicus Therapeutics published news for 2022 q3
SEC form 6
2022-09-14 07:00 ET
Amicus Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 16:08 ET
Amicus Therapeutics reported for 2022 q2
SEC form 6
2022-08-04 07:01 ET
Amicus Therapeutics published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Amicus Therapeutics reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Amicus Therapeutics reported for 2022 q2
SEC form 6
2022-08-01 17:10 ET
Amicus Therapeutics published news for 2022 q2
SEC form 6
2022-06-10 16:05 ET
Amicus Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 16:05 ET
Amicus Therapeutics reported for 2022 q1
SEC form 6
2022-05-10 16:01 ET
Amicus Therapeutics published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Amicus Therapeutics reported for 2022 q1
SEC form 6
2022-05-09 12:54 ET
Amicus Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 07:00 ET
Amicus Therapeutics published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Amicus Therapeutics reported for 2022 q1
SEC form 6
2022-04-26 16:38 ET
Amicus Therapeutics published news for 2022 q1
SEC form 10
2022-02-24 16:19 ET
Amicus Therapeutics published news for 2021 q4
SEC form 6
2022-02-24 07:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 07:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Amicus Therapeutics published news for 2021 q4
SEC form 6
2021-12-03 07:00 ET
Amicus Therapeutics published news for 2021 q3
SEC form 6
2021-11-18 07:01 ET
Amicus Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 16:10 ET
Amicus Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 07:07 ET
Amicus Therapeutics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Amicus Therapeutics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Amicus Therapeutics published news for 2021 q3
SEC form 6
2021-09-29 09:28 ET
Amicus Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 16:10 ET
Amicus Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 07:02 ET
Amicus Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Amicus Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Amicus Therapeutics published news for 2021 q2
SEC form 6
2021-08-02 07:00 ET
Amicus Therapeutics published news for 2021 q2
SEC form 6
2021-06-14 07:27 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-06-08 07:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 16:06 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-05-10 07:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-05-03 07:01 ET
Amicus Therapeutics published news for 2021 q1
SEC form 6
2021-04-27 16:17 ET
Amicus Therapeutics published news for 2021 q1
SEC form 10
2021-03-01 16:21 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-03-01 07:00 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-02-11 16:01 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-02-08 14:30 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 07:00 ET
Amicus Therapeutics published news for 2020 q4
SEC form 6
2020-12-02 07:00 ET
Amicus Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:05 ET
Amicus Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 07:00 ET
Amicus Therapeutics published news for 2020 q3